ZA9610855B - Vitronectin receptor antagonists. - Google Patents
Vitronectin receptor antagonists.Info
- Publication number
- ZA9610855B ZA9610855B ZA9610855A ZA9610855A ZA9610855B ZA 9610855 B ZA9610855 B ZA 9610855B ZA 9610855 A ZA9610855 A ZA 9610855A ZA 9610855 A ZA9610855 A ZA 9610855A ZA 9610855 B ZA9610855 B ZA 9610855B
- Authority
- ZA
- South Africa
- Prior art keywords
- receptor antagonists
- vitronectin receptor
- vitronectin
- antagonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US953295P | 1995-12-29 | 1995-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA9610855B true ZA9610855B (en) | 1997-11-24 |
Family
ID=21738237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9610855A ZA9610855B (en) | 1995-12-29 | 1996-12-23 | Vitronectin receptor antagonists. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0895475A4 (en) |
JP (1) | JP2000502708A (en) |
KR (1) | KR19990076876A (en) |
CN (1) | CN1209060A (en) |
AU (1) | AU1353897A (en) |
BR (1) | BR9612378A (en) |
CA (1) | CA2241724A1 (en) |
CZ (1) | CZ203798A3 (en) |
HU (1) | HUP9901116A2 (en) |
IL (1) | IL125034A0 (en) |
MX (1) | MX9805253A (en) |
NO (1) | NO983002L (en) |
PL (1) | PL327919A1 (en) |
TR (1) | TR199801255T2 (en) |
WO (1) | WO1997024122A1 (en) |
ZA (1) | ZA9610855B (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996006087A1 (en) * | 1994-08-22 | 1996-02-29 | Smithkline Beecham Corporation | Bicyclic compounds |
EP0880511A4 (en) * | 1996-01-16 | 1999-06-16 | Merck & Co Inc | Integrin receptor antagonists |
JP2000508319A (en) * | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αvβ3 antagonist |
US20030125317A1 (en) | 1996-10-02 | 2003-07-03 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
DE19653645A1 (en) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
DE19653647A1 (en) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
JP2002510328A (en) * | 1997-07-25 | 2002-04-02 | スミスクライン・ビーチャム・コーポレイション | Vitronectin receptor antagonist |
EP1047425A4 (en) * | 1997-12-17 | 2009-04-22 | Merck & Co Inc | Integrin receptor antagonists |
HUP0101143A3 (en) * | 1998-03-10 | 2002-12-28 | Smithkline Beecham Corp | Pyridin-carboxylic acid derivatives as vitronectin receptor antagonists, process for producing them and pharmaceutical compositions containing them |
EP1068194B1 (en) * | 1998-04-01 | 2003-11-05 | Janssen Pharmaceutica N.V. | Pde iv inhibiting pyridine derivatives |
GB9812088D0 (en) * | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
SE9803518D0 (en) * | 1998-10-15 | 1998-10-15 | Astra Pharma Prod | Novel compounds |
JP2002536370A (en) | 1999-02-03 | 2002-10-29 | メルク エンド カムパニー インコーポレーテッド | Benzoazepine derivatives as α-V integrin receptor antagonists |
US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
CN1374863A (en) | 1999-07-21 | 2002-10-16 | 惠氏公司 | Bicyclic antagonists selective for the alpha beta integrin |
EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
DE10028575A1 (en) | 2000-06-14 | 2002-03-14 | Basf Ag | integrin |
FR2800067B1 (en) * | 1999-10-21 | 2004-12-17 | Rhodia Chimie Sa | INTERMEDIATES FOR THE MANUFACTURE OF A BENZOFURANE OR NITROGEN BENZOTHIOPHENE DERIVATIVE IN POSITION 5 AND THEIR USES |
FR2820743B1 (en) | 2001-02-09 | 2005-02-25 | Pf Medicament | SYNTHESIS METHOD AND INTERMEDIARIES FOR THE PREPARATION OF PYRIDIN-2-YL-METHYLAMINE DERIVATIVES |
EP2292251A1 (en) | 2001-04-24 | 2011-03-09 | Merck Patent GmbH | Combination therapy using anti-angiogenic agents and TNF-alpha |
AU2004283751B2 (en) * | 2003-10-24 | 2011-05-19 | Exelixis, Inc. | p70S6 kinase modulators and method of use |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
WO2006041046A1 (en) * | 2004-10-13 | 2006-04-20 | Sankyo Company, Limited | Pyridine derivative |
KR20080004554A (en) | 2005-04-20 | 2008-01-09 | 얀센 파마슈티카 엔.브이. | Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls |
AU2007207465B2 (en) | 2006-01-18 | 2012-12-06 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
AR060901A1 (en) * | 2006-05-12 | 2008-07-23 | Jerini Ag | HETEROCICLICAL COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE |
PT2101805E (en) | 2007-01-18 | 2013-01-31 | Merck Patent Gmbh | Integrin ligands for use in treating cancer |
US9345739B2 (en) | 2007-11-08 | 2016-05-24 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
KR20120034666A (en) | 2009-05-22 | 2012-04-12 | 엑셀리시스, 인코포레이티드 | Benzoxazepines based p13k/mtor inthibitors against proliferative diseases |
NZ597339A (en) | 2009-05-25 | 2013-10-25 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
WO2011082967A1 (en) * | 2009-12-17 | 2011-07-14 | Basf Se | Method for producing higher ethanolamines |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
US10328082B2 (en) | 2014-05-30 | 2019-06-25 | Pfizer Inc. | Methods of use and combinations |
WO2017216726A1 (en) | 2016-06-13 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as inhibitors of dnmt1 |
EP4147698A1 (en) | 2017-02-28 | 2023-03-15 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
JP7092784B2 (en) | 2017-02-28 | 2022-06-28 | モーフィック セラピューティック,インコーポレイテッド | αvβ6 integrin inhibitor |
JP2021535141A (en) | 2018-08-29 | 2021-12-16 | モーフィック セラピューティック,インコーポレイテッド | Inhibition of αvβ6 integrin |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627754A (en) * | 1970-05-13 | 1971-12-14 | Hoffmann La Roche | Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts |
AU666318B2 (en) * | 1991-06-28 | 1996-02-08 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
EP0674623B1 (en) * | 1992-12-21 | 2003-04-09 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
EP0762882A4 (en) * | 1994-06-29 | 2002-09-11 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
EP0906103A1 (en) * | 1995-12-29 | 1999-04-07 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
ZA9610853B (en) * | 1995-12-29 | 1998-04-06 | Smithkline Beecham Corp | Processes and intermediates for preparing pharmaceuticals. |
-
1996
- 1996-12-20 CZ CZ982037A patent/CZ203798A3/en unknown
- 1996-12-20 JP JP9524556A patent/JP2000502708A/en active Pending
- 1996-12-20 IL IL12503496A patent/IL125034A0/en unknown
- 1996-12-20 PL PL96327919A patent/PL327919A1/en unknown
- 1996-12-20 BR BR9612378A patent/BR9612378A/en unknown
- 1996-12-20 CA CA002241724A patent/CA2241724A1/en not_active Abandoned
- 1996-12-20 AU AU13538/97A patent/AU1353897A/en not_active Abandoned
- 1996-12-20 WO PCT/US1996/020744 patent/WO1997024122A1/en not_active Application Discontinuation
- 1996-12-20 HU HU9901116A patent/HUP9901116A2/en unknown
- 1996-12-20 EP EP96945085A patent/EP0895475A4/en not_active Withdrawn
- 1996-12-20 KR KR1019980705003A patent/KR19990076876A/en not_active Application Discontinuation
- 1996-12-20 TR TR1998/01255T patent/TR199801255T2/en unknown
- 1996-12-20 CN CN96180099A patent/CN1209060A/en active Pending
- 1996-12-23 ZA ZA9610855A patent/ZA9610855B/en unknown
-
1998
- 1998-06-26 NO NO983002A patent/NO983002L/en not_active Application Discontinuation
- 1998-06-26 MX MX9805253A patent/MX9805253A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR19990076876A (en) | 1999-10-25 |
EP0895475A4 (en) | 2000-08-23 |
BR9612378A (en) | 1999-07-13 |
HUP9901116A2 (en) | 2000-03-28 |
EP0895475A1 (en) | 1999-02-10 |
WO1997024122A1 (en) | 1997-07-10 |
AU1353897A (en) | 1997-07-28 |
CN1209060A (en) | 1999-02-24 |
IL125034A0 (en) | 1999-01-26 |
CZ203798A3 (en) | 1998-12-16 |
TR199801255T2 (en) | 1998-10-21 |
CA2241724A1 (en) | 1997-07-10 |
NO983002D0 (en) | 1998-06-26 |
PL327919A1 (en) | 1999-01-04 |
JP2000502708A (en) | 2000-03-07 |
NO983002L (en) | 1998-08-26 |
MX9805253A (en) | 1998-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA9610854B (en) | Vitronectin receptor antagonists. | |
ZA9610859B (en) | Vitronectin receptor antagonists. | |
ZA9610855B (en) | Vitronectin receptor antagonists. | |
EP0767792A4 (en) | Vitronectin receptor antagonists | |
ZA955391B (en) | Vitronectin receptor antagonists | |
CY2576B1 (en) | Vitronectin receptor antagonists | |
HU9601529D0 (en) | Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists | |
IL125717A0 (en) | Il-8 receptor antagonists | |
ZA969775B (en) | Endothelin receptor antagonists. | |
IL130760A0 (en) | Vitronectin receptor antagonists | |
IL135028A0 (en) | Vitronectin receptor antagonists | |
HUP9902817A3 (en) | Endothelin receptor antagonists | |
HU9602054D0 (en) | Endothelin receptor antagonists | |
EP0854721A4 (en) | Endothelin receptor antagonists | |
ZA966552B (en) | Endothelin receptor antagonists. | |
EP0841926A4 (en) | Endothelin receptor antagonists | |
EP0841916A4 (en) | Endothelin receptor antagonists | |
EP0868180A4 (en) | Endothelin receptor antagonists | |
ZA978798B (en) | Vitronectin receptor antagonists. | |
ZA964195B (en) | Integrin receptor antagonists. | |
ZA9610873B (en) | Integrin receptor antagonists. | |
SI0957917T1 (en) | Vitronectin receptor antagonists | |
ZA988562B (en) | Vitronectin receptor antagonists | |
ZA991884B (en) | Vitronectin receptor antagonists. | |
ZA9610690B (en) | Integrin receptor antagonists. |